-+ 0.00%
-+ 0.00%
-+ 0.00%

Cellectis publishes corporate presentation on gene editing platform, allogeneic CAR-T pipeline

PUBT·05/11/2026 20:56:15
Listen to the news
Cellectis publishes corporate presentation on gene editing platform, allogeneic CAR-T pipeline
  • Cellectis highlighted 4 ongoing allogeneic CAR-T clinical trials, including 2 pivotal Phase 2 programs.
  • Cash position USD 188 million as of March 31, 2026; expected runway into Q4 2027.
  • Key upcoming catalysts include first interim analysis from BALLI-01 pivotal Phase 2 trial of lasme-cel in B-ALL expected in Q4 2026.
  • Company also flagged Q4 2026 timing for full Phase 1 dataset from NATHALI-01 study of eti-cel in NHL.
  • Partnership portfolio described as carrying multi-billion potential milestones; royalties.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellectis SA published the original content used to generate this news brief on May 11, 2026, and is solely responsible for the information contained therein.